Of 3037 patients analyzed, 249 (8%) were ≥80 years. Characteristics of the study population are presented in Table I. The elderly population was more likely to be female and had a longer history of ...

A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a ...

A new drug ranolazine is a safe and effective treatment for chronic stable angina and adds to the treatment options for patients with this condition. The treatment is discussed in a New Drug Class ...

Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with ...

Corautus Genetics Inc. (NASDAQ:VEGF) announced today the publication of the two year follow-up results of the Corautus' earlier Phase I study of VEGF-2 in patients with severe angina. In this trial, ...

Please provide your email address to receive an email when new articles are posted on . New data from the phase 2 COSIRA trial demonstrate that implantation of a coronary-sinus reducing device was ...

(HealthDay News) — A stent-like device placed in the coronary sinus may benefit patients with refractory angina, according to a small clinical trial published in the Feb. 5 issue of the New England ...

An entirely predictable consequence of medical progress is the growing number of heart patients with persistent and symptomatic angina who have run out of treatment options. A small study published in ...

Real-world results suggest narrowing the coronary sinus with the Reducer (Neovasc) stent may provide durable relief for patients with refractory angina unsuitable for further revascularization. The ...

The Seattle Angina Questionnaire (SAQ), designed to assess the impact of ischemic heart disease on a patient’s symptoms, functions, and quality of life, works as well in women as it does in men, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A percutaneous ...

VANCOUVER and MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in ...